Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood

0
37

    • Benova L.
    • Mohamoud Y.A.
    • Calvert C.
    • Abu-Raddad L.J.

    Vertical transmission of hepatitis C virus: systematic review and meta-analysis.

    Clin Infect Dis. 2014; 59: 765-773

    • Indolfi G.
    • Azzari C.
    • Resti M.

    Perinatal transmission of hepatitis C virus.

    J Pediatr. 2013; 163 (): 1549

    • Schmelzer J.
    • Dugan E.
    • Blach S.
    • Coleman S.
    • Cai Z.
    • DePaola M.
    • et al.

    Global prevalence of hepatitis C virus in children in 2018: a modelling study.

    Lancet Gastroenterol Hepatol. 2020; 5: 374-392

    • Goodman Z.D.
    • Makhlouf H.R.
    • Liu L.
    • Balistreri W.
    • Gonzalez-Peralta R.P.
    • Haber B.
    • et al.

    Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.

    Hepatology. 2008; 47: 836-843

    • Strickland D.K.
    • Jenkins J.J.
    • Hudson M.M.

    Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer.

    J Pediatr Hematol Oncol. 2001; 23: 527-529

    • Mohan P.
    • Colvin C.
    • Glymph C.
    • Chandra R.R.
    • Kleiner D.E.
    • Patel K.M.
    • et al.

    Clinical spectrum and histopathologic features of chronic hepatitis C infection in children.

    J Pediatr. 2007; 150 (): 168-174

    • Gonzalez-Peralta R.P.
    • Langham Jr., M.R.
    • Andres J.M.
    • Mohan P.
    • Colombani P.M.
    • Alford M.K.
    • et al.

    Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C.

    J Pediatr Gastroenterol Nutr. 2009; 48: 630-635

    • Nydegger A.
    • Srivastava A.
    • Wake M.
    • Smith A.L.
    • Hardikar W.

    Health-related quality of life in children with hepatitis C acquired in the first year of life.

    J Gastroenterol Hepatol. 2008; 23: 226-230

    • Rodrigue J.R.
    • Balistreri W.
    • Haber B.
    • Jonas M.M.
    • Mohan P.
    • Molleston J.P.
    • et al.

    Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.

    J Pediatr Gastroenterol Nutr. 2009; 48: 341-347

    • Erman A.
    • Krahn M.D.
    • Hansen T.
    • Wong J.
    • Bielecki J.M.
    • Feld J.J.
    • et al.

    Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.

    BMJ Open. 2019; 9e027491

    • Delgado-Borrego A.
    • Healey D.
    • Negre B.
    • Christofi M.
    • Sabharwal S.
    • Ludwig D.A.
    • et al.

    Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.

    J Pediatr Gastroenterol Nutr. 2010; 51: 191-197

    • van der Meer A.J.
    • Veldt B.J.
    • Feld J.J.
    • Wedemeyer H.
    • Dufour J.F.
    • Lammert F.
    • et al.

    Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

    Jama. 2012; 308: 2584-2593

    • Krahn M.
    • Wong J.B.
    • Heathcote J.
    • Scully L.
    • Seeff L.

    Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990.

    Med Decis Making. 2004; 24: 20-29

  • Canada S. Table 13-10-0114-01 Life expectancy and other elements of the life table, Canada, all provinces except Prince Edward Island 2018 [cited 2013-2015.

    • D’Amico G.
    • Garcia-Tsao G.
    • Pagliaro L.

    Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

    J Hepatol. 2006; 44: 217-231

    • Altekruse S.F.
    • McGlynn K.A.
    • Reichman M.E.

    Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27: 1485-1491

    • Charlton M.
    • Seaberg E.
    • Wiesner R.
    • Everhart J.
    • Zetterman R.
    • Lake J.
    • et al.

    Predictors of patient and graft survival following liver transplantation for hepatitis C.

    Hepatology. 1998; 28: 823-830

  • Hunink MGM, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Second Edition ed. Cambridge, United Kingdom: Cambridge University Press; 2014. 424 p.

    • Saeed Y.A.
    • Phoon A.
    • Bielecki J.M.
    • Mitsakakis N.
    • Bremner K.E.
    • Abrahamyan L.
    • et al.

    A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C.

    Value Health. 2020; 23: 127-137

  • Haines A YZ, Thein H, Wong W, Krahn M. State-specific direct medical costs of hepatitis C in Ontario: A population-level study 2019 [Available from: https://canlivj.utpjournals.press/doi/full/10.3138/canlivj.2019-abstract.

    • Lapointe-Shaw L.
    • Georgie F.
    • Carlone D.
    • Cerocchi O.
    • Chung H.
    • Dewit Y.
    • et al.

    Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.

    PLoS One. 2018; 13e0201120

  • Table 18-10-0005-01 Consumer Price Index, annual average, not seasonally adjusted [Internet]. Statistics Canada. 2020 [cited Feb 5, 2020]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000501.

  • Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person-level costing using administrative databases in Ontario. 2013.

  • Secrecy on cost of publicly funded hep C treatment.

    Cmaj. 2017; 189 ()

    • Balistreri W.F.
    • Murray K.F.
    • Rosenthal P.
    • Bansal S.
    • Lin C.H.
    • Kersey K.
    • et al.

    The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.

    Hepatology. 2017; 66: 371-378

    • Murray K.F.
    • Balistreri W.F.
    • Bansal S.
    • Whitworth S.
    • Evans H.M.
    • Gonzalez-Peralta R.P.
    • et al.

    Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.

    Hepatology. 2018; 68: 2158-2166

    • Jonas M.M.
    • Squires R.H.
    • Rhee S.M.
    • Lin C.W.
    • Bessho K.
    • Feiterna-Sperling C.
    • et al.

    Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.

    Hepatology. 2020; 71: 456-462

    • Neumann P.J.
    • Cohen J.T.
    • Weinstein M.C.

    Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold.

    N Engl J Med. 2014; 371: 796-797

    • Nguyen J.
    • Barritt ASt
    • Jhaveri R.

    Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.

    J Pediatr. 2019; 207: 90-96

  • Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

    Hepatology. 2020; 71: 686-721

    • Chahal H.S.
    • Marseille E.A.
    • Tice J.A.
    • Pearson S.D.
    • Ollendorf D.A.
    • Fox R.K.
    • et al.

    Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

    JAMA internal medicine. 2016; 176: 65-73

  • Source link

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here